Gam-COVID-Vac

Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

Thursday, October 29, 2020 - 6:19am

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.
  • Further, the Company will have access to Good Clinical Laboratory Practice (GCLP) labs to conduct immunogenicity assay testing of the vaccine.
  • Satish Reddy, Chairman, Dr. Reddys Laboratories said, We are pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India.
  • We look forward to working with them to accelerate our efforts in bringing the vaccine to India.

Russian application of Sputnik V vaccine for WHO vaccine prequalification among the first applications submitted

Tuesday, October 27, 2020 - 5:13pm

The Russian Federation has become one of the first countries to apply to WHO for prequalification of its vaccine against the novel coronavirus infection.

Key Points: 
  • The Russian Federation has become one of the first countries to apply to WHO for prequalification of its vaccine against the novel coronavirus infection.
  • The Prequalification of Medicines Programme is a United Nations programme managed by WHO.
  • Successful prequalification will enable Sputnik V to be included in the list of medicines used by international procurement agencies and countries to guide bulk purchasing of medicines.
  • We have submitted an application for Emergency Use Listing and prequalification of the vaccine by the World Health Organization, which will allow Sputnik V to be included in the list of medical products that meet leading quality, safety and efficacy standards.

Russian application of Sputnik V vaccine for WHO vaccine prequalification among the first applications submitted

Tuesday, October 27, 2020 - 5:09pm

The Russian Federation has become one of the first countries to apply to WHO for prequalification of its vaccine against the novel coronavirus infection.

Key Points: 
  • The Russian Federation has become one of the first countries to apply to WHO for prequalification of its vaccine against the novel coronavirus infection.
  • The Prequalification of Medicines Programme is a United Nations programme managed by WHO.
  • Successful prequalification will enable Sputnik V to be included in the list of medicines used by international procurement agencies and countries to guide bulk purchasing of medicines.
  • We have submitted an application for Emergency Use Listing and prequalification of the vaccine by the World Health Organization, which will allow Sputnik V to be included in the list of medical products that meet leading quality, safety and efficacy standards.

Dr. Reddy’s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

Saturday, October 17, 2020 - 11:44am

Earlier in September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.

Key Points: 
  • Earlier in September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.
  • As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddys upon regulatory approval in India.
  • This data will further strengthen the clinical development of Sputnik V vaccine in India.
  • Sputnik V is currently undergoing phase 3 clinical trial in Russia and the proposed number of subjects is 40,000.

Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine

Wednesday, October 14, 2020 - 1:00pm

Given that the hamster is a great model for assessing severe infection, this study helps to validate our vaccines potential to provide potent protection against COVID-19.

Key Points: 
  • Given that the hamster is a great model for assessing severe infection, this study helps to validate our vaccines potential to provide potent protection against COVID-19.
  • These results increase our confidence as we move our vaccine candidate into human clinical trials.
  • The study evaluated Vaxarts recombinant adenoviral vaccine, with doses given at 0 and 4 weeks.
  • These results support the efficacy potential of our oral COVID-19 vaccine candidate suggested by our earlier pre-clinical data, said Andrei Floroiu, chief executive officer ofVaxart.

Americans Split Over Safety of Vaccines; 36% Say They Won't Take COVID-19 Vaccine When Made Available

Thursday, October 8, 2020 - 4:52pm

While a slight majority (51%) of American likely voters say they will take the COVID-19 vaccine when available, 36% say no, leaving 14% unsure.In other words, exactly half of the population are unwilling and hesitant about getting the COVID-19 vaccine.

Key Points: 
  • While a slight majority (51%) of American likely voters say they will take the COVID-19 vaccine when available, 36% say no, leaving 14% unsure.In other words, exactly half of the population are unwilling and hesitant about getting the COVID-19 vaccine.
  • When asked about reasons for not getting the vaccine, the most common answer (59%) is "afraid of vaccine side effects ."
  • A follow-up question asked respondents how safe they believe the COVID-19 vaccine would be when made available.
  • The most common answer among the nearly three in ten Americans who believe the vaccine will be unsafe, cite "rushed/needs more testing" as a concern .

RDIF announces delivery of the first batch of Sputnik V vaccine to Venezuela for clinical trials

Friday, October 2, 2020 - 8:59pm

MOSCOW, Oct. 2, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, announces the delivery of the first batch of the Russian vaccine against coronavirus, Sputnik V, to the Bolivarian Republic of Venezuela.

Key Points: 
  • MOSCOW, Oct. 2, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, announces the delivery of the first batch of the Russian vaccine against coronavirus, Sputnik V, to the Bolivarian Republic of Venezuela.
  • Vaccination of volunteers in Venezuela will begin in coming days as part of double-blind, randomized, placebo-controlled clinical trials of the Sputnik V vaccine.
  • Venezuela has become the first country in Latin America to start clinical trials of the Sputnik V vaccine after its registration in Russia with 2000 people taking part in the trial.
  • Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently ongoing.

Health Canada begins first authorization review of a COVID-19 vaccine submission

Friday, October 2, 2020 - 2:27pm

OTTAWA, ON, Oct. 2, 2020 /CNW/ - Yesterday, Health Canada received its first submission for authorization of a COVID-19 vaccine developed by AstraZeneca in partnership with the University of Oxford.

Key Points: 
  • OTTAWA, ON, Oct. 2, 2020 /CNW/ - Yesterday, Health Canada received its first submission for authorization of a COVID-19 vaccine developed by AstraZeneca in partnership with the University of Oxford.
  • Health Canada will be doing a rolling review of AstraZeneca's vaccine data to make sure it meets the Department's rigorous safety and efficacy requirements.
  • Following the authorization of any vaccine submission, Health Canada will publish the evidence it reviewed in making its decision for transparency.
  • Earlier this month, the Prime Minister announced that Canada has signed an agreement with AstraZeneca to buy 20 million doses of its COVID-19 vaccine, should that vaccine successfully complete clinical trials and be authorized by Health Canada.

Informa Pharma Intelligence Launches New Pulse Report: Clinical Trials & the COVID-19 Vaccine

Thursday, October 1, 2020 - 4:00pm

LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today released its Pulse Report: Clinical Trials & the COVID-19 Vaccine study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials.

Key Points: 
  • LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today released its Pulse Report: Clinical Trials & the COVID-19 Vaccine study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials.
  • According to the data, more than 1 in 3 (35%) Americans dont trust how quickly the COVID-19 vaccine clinical trials are moving, and more than 1 in 5 (23%) dont think pharmaceutical companies have consumers best interests at mind during COVID-19 vaccine clinical trials.
  • Right now, 1 in 5 Americans agree that both pharmaceutical companies and the government are NOT communicating enough about COVID-19 vaccine clinical trials (20% and 21% respectively).
  • Many Americans say theyre more likely to take the COVID-19 vaccine if they:
    Had more information on clinical trials: more than 1 in 4 (28%)
    Knew the demographic breakdowns of clinical trials were diverse: almost 1 in 6 (15%)
    Could directly ask questions about clinical trials to vaccine developers: more than 1 in 10 (12%)
    Knew someone who had participated in a clinical trial: more than 1 in 10 (11%)
    Theres a clear demand for unbiased information from the American public when it comes to COVID-19 vaccine clinical trials, said Duncan Emerton, PhD, Director, Custom Intelligence & Analytics, Pharma Intelligence.

Top American doctors and medical workers take part in a first briefing on the Sputnik V vaccine in the United States by Russia's Gamaleya Center scientists

Tuesday, September 29, 2020 - 11:34am

All the medical professionals who took part in the briefing have had extensive practical experience of COVID-19 treatment in recent months.

Key Points: 
  • All the medical professionals who took part in the briefing have had extensive practical experience of COVID-19 treatment in recent months.
  • The Gamaleya Center scientists told the U.S. audience in detail about the key stages of the development of Sputnik V, including the results of earlier clinical trials and the progress of an ongoing post-registration clinical trial.
  • Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently ongoing.
  • If the vaccine performs as the data suggests, you have a very good vaccine on your hands.